“We can now cure 19 out of 20 cases of testicular cancer, but a significant number of testicular cancer survivors have low testosterone, and that can affect other aspects of their health. Based on this study and others, clinicians should ask testis cancer survivors whether they have symptoms of low testosterone and should watch for signs of associated health problems,” said Timothy D. Gilligan, MD, MSc, ASCO Expert.
CHICAGO – In a large study, 38% of 491 testicular cancer survivors had low testosterone levels, known as hypogonadism. Compared to survivors with normal testosterone levels, survivors with low testosterone were more likely to have a range of chronic health problems, including high blood pressure, diabetes, erectile dysfunction, and anxiety or depression.
The study will be featured in a press briefing today and presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
“Because testicular cancer occurs at a young age and is highly curable, many survivors may live upwards of five decades,” said lead study author Mohammad Issam Abu Zaid, MBBS, an Assistant Professor of Medicine at the Indiana University School of Medicine in Indianapolis, Indiana. “Our findings underscore the need for clinicians to assess testicular cancer survivors for physical signs or symptoms of hypogonadism and to measure testosterone levels in those who do.”
Low testosterone can be present at the time of a testicular cancer diagnosis, or it can develop as a side effect of surgery or chemotherapy. While it has been known that low testosterone occurs in a significant proportion of testicular cancer survivors, this is one of the first studies to examine its relationship with long-term health complications in North American patients.
About the Study
This analysis comes from the first 491 patients enrolled in The Platinum Study, which aims to be the largest study of testicular cancer survivors worldwide, with over 1,600 survivors already enrolled and still actively recruiting. All patients received chemotherapy and were younger than 55 when they were diagnosed with cancer. The median age at clinical evaluation was 38 years.
The goal of the Platinum Study is to follow the lifelong health of men who received cisplatin chemotherapy for testicular cancer. Researchers collect health information through comprehensive questionnaires and blood samples, as well as basic measurements like blood pressure and a hearing test. The study also aims to identify genes that may raise the chance of developing long-term health problems, such as nerve damage and hearing loss. The study is funded by the National Cancer Institute, National Institutes of Health.
Among the 491 survivors, 38% had a low testosterone level or were on testosterone replacement therapy. Being overweight or obese was associated with a higher chance of having low testosterone, as was older age. The researchers also found a genetic abnormality (in the sex hormone binding globulin gene) that appears to predispose some men to low testosterone, but this needs to be confirmed in larger studies. Survivors participating in vigorous physical activity appeared to have higher levels of testosterone.
Compared to survivors with normal testosterone, testicular cancer survivors with low testosterone were more likely to take medicine for:
- High cholesterol (20% vs. 6%)
- High blood pressure (19% vs. 11%)
- Erectile dysfunction (20% vs. 12%)
- Diabetes (6% vs. 3%)
- Anxiety or depression (15% vs. 10%)
“Some of these health problems have been previously linked to low testosterone levels among men in the general population and in a few studies of testicular cancer survivors, but this study is one of the most comprehensive to date – we are looking at 15 different health conditions,” said Dr. Abu Zaid.
The researchers will continue to follow this group of survivors and expand the analysis to the entire cohort of 1,600 survivors enrolled on the study to date. They also plan to eventually enroll a group of survivors who were cured with surgery only, to parse out the effects of surgery vs. chemotherapy on the development of adverse health outcomes and further examine testosterone levels.
This study was funded by the National Institutes of Health.
View the full abstract.
For your readers:
View the disclosures for the 2017 ASCO Annual Meeting News Planning Team.
ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.